Adenovirus-mediated human tissue kallikrein gene delivery induces angiogenesis in normoperfused skeletal muscle

被引:70
作者
Emanueli, C
Zacheo, A
Minasi, A
Chao, J
Chao, L
Salis, MB
Stacca, T
Straino, S
Capogrossi, MC
Madeddu, P
机构
[1] Natl Inst Biostruct & Biosyst, Natl Lab, Osilo, Italy
[2] IRCCS, IDI, Lab Patol Vasc, Rome, Italy
[3] Med Univ Sassari, Inst Internal Med, Sassari, Italy
[4] Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA
关键词
gene delivery; angiogenesis; kallikrein; kinins; nitric oxide;
D O I
10.1161/01.ATV.20.11.2379
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We investigated whether local delivery of the tissue kallikrein gene induces angiogenesis in normoperfused mouse hindlimb muscles. Intramuscular injection of adenovirus containing the human tissue kallikrein gene under the control of a cytomegalovirus enhancer/promoter sequence resulted in local production and release of recombinant human tissue kallikrein, whereas transgene expression was absent in muscles of the contralateral hindlimb. Angiogenesis in infected muscles was documented by histological evidence of increased capillary density. In contrast, no angiogenic effect was seen either in the ipsilateral gastrocnemius or contralateral hindlimb muscles. Neovascularization was associated with a transient increase in muscular bloodflow as determined by laser Doppler flowmetry. We also investigated the mechanisms of kallikrein-induced angiogenesis, We found that the angiogenic response to kallikrein was abolished by chronic blockade of the kinin B-1 or B-2 receptor or by inhibition of nitric oxide synthase. In addition, inhibition of cyclooxygenase-2 by nimesulide significantly reduced kallikrein-induced effects. These results indicate that (1) human tissue kallikrein acts as an angiogenic factor in normoperfused skeletal muscle and (2) nitric oxide and prostacyclin are essential mediators of kallikrein-induced angiogenesis. Our findings provide new insights into the role of the tissue kallikrein-kinin system in vascular biology.
引用
收藏
页码:2379 / 2385
页数:7
相关论文
共 50 条
[31]   IN-VIVO ANGIOGENESIS INDUCED BY RECOMBINANT ADENOVIRUS VECTORS CODING EITHER FOR SECRETED OR NONSECRETED FORMS OF ACIDIC FIBROBLAST GROWTH-FACTOR [J].
MUHLHAUSER, J ;
PILI, R ;
MERRILL, MJ ;
MAEDA, H ;
PASSANITI, A ;
CRYSTAL, RG ;
CAPOGROSSI, MC .
HUMAN GENE THERAPY, 1995, 6 (11) :1457-1465
[32]   VEGF(165) EXPRESSED BY A REPLICATION-DEFICIENT RECOMBINANT ADENOVIRUS VECTOR INDUCES ANGIOGENESIS IN-VIVO [J].
MUHLHAUSER, J ;
MERRILL, MJ ;
PILI, R ;
MAEDA, H ;
BACIC, M ;
BEWIG, B ;
PASSANITI, A ;
EDWARDS, NA ;
CRYSTAL, RG ;
CAPOGROSSI, MC .
CIRCULATION RESEARCH, 1995, 77 (06) :1077-1086
[33]   Kallikrein gene delivery inhibits vascular smooth muscle cell growth and neointima formation in the rat artery after balloon angioplasty [J].
Murakami, H ;
Yayama, K ;
Miao, RQ ;
Wang, C ;
Chao, L ;
Chao, J .
HYPERTENSION, 1999, 34 (02) :164-170
[34]   Nitric oxide synthase modulates angiogenesis in response to tissue ischemia [J].
Murohara, T ;
Asahara, T ;
Silver, M ;
Bauters, C ;
Masuda, H ;
Kalka, C ;
Kearney, M ;
Chen, DH ;
Chen, DF ;
Symes, JF ;
Fishman, MC ;
Huang, PL ;
Isner, JM .
JOURNAL OF CLINICAL INVESTIGATION, 1998, 101 (11) :2567-2578
[35]   Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia [J].
Newman, KD ;
Dunn, PF ;
Owens, JW ;
Schulick, AH ;
Virmani, R ;
Sukhova, G ;
Libby, P ;
Dichek, DA .
JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (06) :2955-2965
[36]   Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle [J].
Poliakova, L ;
Kovesdi, I ;
Wang, XT ;
Capogrossi, MC ;
Talan, M .
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1999, 118 (02) :339-347
[37]   ANGIOGENIC GROWTH-FACTOR AND REVASCULARIZATION OF THE ISCHEMIC LIMB - EVALUATION IN A RABBIT MODEL [J].
PU, LQ ;
SNIDERMAN, AD ;
AREKAT, Z ;
GRAHAM, AM ;
BRASSARD, R ;
SYMES, JF .
JOURNAL OF SURGICAL RESEARCH, 1993, 54 (06) :575-583
[38]  
REGOLI D, 1980, PHARMACOL REV, V32, P1
[39]   Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA [J].
Rosengart, TK ;
Lee, LY ;
Patel, SR ;
Kligfield, PD ;
Okin, PM ;
Hackett, NR ;
Isom, OW ;
Crystal, RG .
ANNALS OF SURGERY, 1999, 230 (04) :466-470
[40]   Angiogenesis gene therapy - Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease [J].
Rosengart, TK ;
Lee, LY ;
Patel, SR ;
Sanborn, TA ;
Parikh, M ;
Bergman, GW ;
Hachamovitch, R ;
Szulc, M ;
Kligfield, PD ;
Okin, PM ;
Hahn, RT ;
Devereux, RB ;
Post, MR ;
Hackett, NR ;
Foster, T ;
Grasso, TM ;
Lesser, ML ;
Isom, OW ;
Crystal, RG .
CIRCULATION, 1999, 100 (05) :468-474